RTI-HS prepared economic models, submission dossiers and assisted clients in responding to the consultations for three oncology products appraised by NICE via the new STA process in the United Kingdom:

• The submission for docetaxel (Taxotere®, sanofi-aventis) for early breast cancer was among the first submissions made via the interim STA process in February, 2006. The final appraisal determination was published July 18, 2006; Taxotere was recommended within its licensed indication without restriction.
• Two further oncology submissions are currently under review.

Our most recent submission is following the Final STA Process approved at the NICE Board Meeting in May, 2006.

Additional Resources:

• Final STA Approved Process Guide, approved at the NICE Board Meeting in May, 2006
• Changes from interim process recommended to the Board
• Diagram of the STA process:

• Points in the process at which additional information or clarification may be requested: